Antibody kinetics and immune profile analysis of a Streptococcus equi DNA vaccine expressing the FljB and SeM fusion protein in murine and equine models.

The research article discusses the development and testing of a promising DNA vaccine for Strangles, a highly infectious disease that affects horses. The scientists successfully created a vaccine that fused two antigens: one from the disease-causing bacterium streptococcus equi, and another from the bacterium salmonella abortus equi. The vaccine was tested on mice and horses and triggered both Th1 and Th2 immune responses, providing better protection against infection than previous methods.

Vaccine Development

The scientists in this study aimed to develop a more effective vaccine against Strangles, a common horse disease caused by the Streptococcus equi subspecies equi (S. equi) bacterium.

• They constructed a new type of DNA vaccine by combining the SeM antigen from S. equi with the FljB flagellin protein from Salmonella abortus equi.
• This fusion vaccine was hypothesized to illicit a stronger immune response than a vaccine containing the SeM antigen alone.

Vaccine Testing

The research team tested the new FljB-SeM DNA vaccine on mice and horses to assess its safety and effectiveness.

• Animals were given the vaccine through an intramuscular injection.
• The vaccine successfully induced a strong immune response in both mice and horses.
• Reactions included high levels of specific antibodies and increased production of cytokines, IFN-γ and IL-4, suggesting activation of both Th1 and Th2 type immune cells.

Results and Implications

The research article suggests that the newly created FljB-SeM DNA vaccine was more effective than previous vaccines.

• Mice immunized with this vaccine had significantly higher survival rates compared to those immunized with SeM alone.
• This indicates that effectively integrating the FljB and SeM proteins may enhance the immune response and provide better protection against S. equi.
• The results of this study could help advance the development of a powerful, cost-effective vaccine to combat strangles in horses.